Avid Bioservices Inc (CDMO)

[dia76ca]

When I look at the liver cancer data it does indicate that a very high percentage of patients have either HCV or HBV. And it does appear that HBV patients do worse than HCV with sorafenib treatment. I am wondering if the fact that Bavi as a monotherapy has a modest effect against HCV might indicate that it will also have at least a modest effect against HBV? If so we might see a significant improvement in results from both of these groups. The pre-clinical Bavi results are very encouraging. I would not be surprised to see at least a doubling of MOS in the liver trial.